Multitargeted agents for therapeutically challenging tumor: an introduction for oncology nurses.
King
Cynthia R
CR
Wake Forest University Baptist Medical Center, Winston Salem, NC, USA.
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000009:adverse effects / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D016503:Drug Delivery Systems / Q000379:methods* / Q000451:nursing; D016903:Drug Monitoring / Q000451:nursing; D046152:Gastrointestinal Stromal Tumors / Q000628:therapy*; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000628:therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D024802:Nurse's Role; D009730:Nursing Assessment; D009859:Oncology Nursing / Q000458:organization & administration*; D010353:Patient Education as Topic; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use; D015398:Signal Transduction; D000077157:Sorafenib; D000077210:Sunitinib
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D000077210:Sunitinib